Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-c...

por Wolf, J., Helland, Å., Oh, I.-J., Migliorino, M.R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V., Novello, S.
Publicado 2022

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado 2018